Abstract
High levels of decoy receptor 2 (DcR2; TRAIL-R4) expression are correlated with TRAIL resistance in prostate cancer cells. In addition, upregulation of TRAIL death receptor (DR4 and DR5) expression, either by ionizing radiation or chemotherapy, can sensitize cancer cells to TRAIL. Considering more than half of human cancers are TRAIL resistant, modulation of surface TRAIL receptor expression appears to be an attractive treatment modality to counteract TRAIL resistance. In this study, three siRNA duplexes targeting DcR2 receptor were tested. Ad5hTRAIL infections were performed to overexpress human full-length TRAIL to induce cell death, and the in vitro tumorigenic potential of prostate cancer cells was assessed using colony-forming assays on soft agar. The DU145 and LNCaP prostate cancer cell lines, which express high levels of DcR2, were resistant to Ad5hTRAIL-induced death. Downregulation of surface DcR2 expression by siRNA sensitized these prostate cancer cell lines to Ad5hTRAIL. In addition, DcR2 siRNA-mediated knockdown of DcR2, followed by Ad5hTRAIL infection, dramatically reduced the in vitro tumorigenic potential of prostate cancer cells. Collectively, our results suggest the potential for combining receptor-specific siRNA with TRAIL in the treatment of certain cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Griffith TS, Lynch DH . TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559–563.
Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999; 162: 2597–2605.
Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ . Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833–2840.
Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res 2002; 62: 3093–3099.
Held J, Schulze-Osthoff K . Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 2001; 4: 243–252.
Sanlioglu AD, Koksal T, Baykara M, Luleci G, Karacay B, Sanlioglu S . Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Gene Ther Mol Biol 2003; 7: 113–133.
Kondo K, Yamasaki S, Sugie T, Teratani N, Kan T, Imamura M et al. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer 2006; 118: 230–242.
Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F . Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. Biochem Pharmacol 2006; 71: 791–798.
Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA . Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 2005; 65: 11447–11458.
He Q, Huang Y, Sheikh MS . Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004; 23: 2554–2558.
Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK . The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004; 24: 1133–1140.
Shankar S, Singh TR, Srivastava RK . Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms. Prostate 2004; 61: 35–49.
Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ . Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004; 11: 681–690.
Wang X, Ju W, Renouard J, Aden J, Belinsky SA, Lin Y . 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res 2006; 66: 1089–1095.
Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S . Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 2006; 13: 21–31.
Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC . Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp Ther Oncol 2005; 5: 81–91.
Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, Wiestler O et al. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006; 11: 1503–1512.
Li X, Raikwar SP, Liu YH, Lee SJ, Zhang YP, Zhang S et al. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol Cancer Ther 2006; 5: 676–684.
Hu H, Jiang C, Schuster T, Li GX, Daniel PT, Lu J . Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol Cancer Ther 2006; 5: 1873–1882.
Fulda S, Debatin KM . 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 2006; 25: 5125–5133.
Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL . Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 2886–2894.
Sanlioglu S, Engelhardt JF . Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways. Gene Therapy 1999; 6: 1427–1437.
Sanlioglu AD, Karacay B, Benson PK, Engelhardt JF, Sanlioglu S . Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Virus Res 2004; 104: 51–59.
Engelhardt JF, Yang Y, Stratford-Perricaudet LD, Allen ED, Kozarsky K, Perricaudet M et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet 1993; 4: 27–34.
Doerschug K, Sanlioglu S, Flaherty DM, Wilson RL, Yarovinsky T, Monick MM et al. First-generation adenovirus vectors shorten survival time in a murine model of sepsis. J Immunol 2002; 169: 6539–6545.
Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S . Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005; 5: 54.
Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther 2007; 18: 39–50.
Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S . Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol 2007; 177: 359–364.
Malhi H, Gores GJ . TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 2006; 25: 7333–7335.
Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA . Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006; 66: 5867–5874.
Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006; 119: 944–954.
VanOosten RL, Moore JM, Karacay B, Griffith TS . Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005; 4: 1104–1112.
Earel Jr JK, VanOosten RL, Griffith TS . Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006; 66: 499–507.
VanOosten RL, Earel Jr JK, Griffith TS . Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther 2006; 13: 628–632.
Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A . Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett 2006; 580: 1925–1931.
Wenger T, Mattern J, Penzel R, Gassler N, Haas TL, Sprick MR et al. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ 2006; 13: 1740–1751.
Terzioglu E, Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 783–789.
Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jegou B, Patard JJ et al. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 2006; 66: 987–995.
Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612–624.
Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S . Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007; 26: 248–257.
Nakao K, Hamasaki K, Ichikawa T, Arima K, Eguchi K, Ishii N . Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol Rep 2006; 16: 389–392.
Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S . TRAIL-R4 decoy receptor gene expression is correlated with high Gleason scores, PSA recurrence and decreased survival in patients with prostate carcinoma. Urol Oncol (in press).
Acknowledgements
This research is funded by the Akdeniz University Scientific Research Project Administration Division and the Health Science Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sanlioglu, A., Karacay, B., Koksal, I. et al. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 14, 976–984 (2007). https://doi.org/10.1038/sj.cgt.7701087
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7701087
Keywords
This article is cited by
-
Optimization Studies on Prokaryotic Cell Expression of the Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)
Cell Biochemistry and Biophysics (2015)
-
MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells
Molecular and Cellular Biochemistry (2014)
-
Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
Cell Death & Disease (2013)
-
Role of TNF-related apoptosis-inducing ligand (TRAIL) in the pathogenesis of varicocele-induced testicular dysfunction
Asian Journal of Andrology (2013)
-
Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis
Cancer Cell International (2011)